| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
CMP-Sialic acid sodium salt targets sialyltransferases, a family of enzymes that catalyze the transfer of sialic acid from CMP-sialic acid to acceptor glycans. It serves as the donor substrate for these enzymes, providing the sialic acid moiety for the sialylation of glycoproteins and glycolipids. This process is essential for the proper function of cell surface glycoconjugates, which are involved in cell-cell recognition, signaling, and immune responses. The compound also acts as an allosteric inhibitor of UDP-GlcNAc 2-epimerase, providing feedback regulation of sialic acid biosynthesis.
|
|---|---|
| ln Vitro |
Neu5Gc in nighttime objects can be detected using the CMAH substrate formed by CMP-sialic acid sodium salt (22.5 μM, 45 min) [1].
In vitro, CMP-Sialic acid sodium salt is used as a substrate for sialyltransferase assays. The enzyme activity is measured by monitoring the transfer of radiolabeled or fluorescently labeled sialic acid from CMP-sialic acid to an acceptor substrate. The compound is also used in the synthesis of sialylated glycoconjugates for structural and functional studies. Additionally, its inhibitory effect on UDP-GlcNAc 2-epimerase can be studied by measuring the conversion of UDP-GlcNAc to ManNAc in the presence of the compound. |
| ln Vivo |
In vivo, CMP-Sialic acid sodium salt plays a critical role in the biosynthesis of sialic acid-containing glycoconjugates. Sialylation is essential for the proper function of many proteins and lipids, and its dysregulation is associated with various diseases, including cancer, inflammation, and viral infections. CMP-Sialic acid sodium salt is not administered as a therapeutic agent but is studied for its role in these processes. The compound's levels in cells are tightly regulated by the balance between its synthesis and consumption.
|
| Enzyme Assay |
In vitro enzyme assays for CMP-Sialic acid sodium salt involve measuring the activity of sialyltransferases. The assay is performed by incubating the enzyme with CMP-sialic acid and an acceptor substrate, such as asialo-α₁-acid glycoprotein or a synthetic glycan. The reaction is carried out in a buffer containing manganese ions at pH 6.5-7.5. The transfer of sialic acid is measured by detecting the incorporation of radiolabeled or fluorescently labeled sialic acid. The compound's inhibitory effect on UDP-GlcNAc 2-epimerase is measured by a coupled enzyme assay.
|
| Cell Assay |
In vitro cellular experiments for CMP-Sialic acid sodium salt involve studying its role in sialylation in cultured cells. Cells are treated with inhibitors of sialic acid biosynthesis or sialyltransferase activity, and the levels of sialylated glycoconjugates are measured using lectin blotting or mass spectrometry. The effect of modulating sialylation on cell functions such as adhesion, migration, and signaling is also studied. CMP-Sialic acid sodium salt can be added to cell culture media to study the effects of exogenous sialic acid on cellular sialylation.
|
| Animal Protocol |
In vivo animal studies for CMP-Sialic acid sodium salt involve measuring its levels in tissues and studying its role in sialylation. The compound is extracted from tissues and analyzed by LC-MS. Its levels are often used as a marker of sialic acid metabolism. Studies in animal models of cancer and inflammation have investigated alterations in sialylation and the levels of CMP-sialic acid. The compound's role in viral infections, where sialic acid is used as a receptor for viral entry, has also been studied.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not typically studied for CMP-Sialic acid sodium salt, as it is an endogenous metabolite rather than a therapeutic agent. However, its levels in the body are dynamically regulated in response to metabolic demands. The compound is synthesized from UDP-GlcNAc via the action of UDP-GlcNAc 2-epimerase and CMP-sialic acid synthase. It is consumed by sialyltransferases in the Golgi apparatus. Its concentration in cells is typically in the micromolar range.
|
| Toxicity/Toxicokinetics |
Toxicology is not applicable to CMP-Sialic acid sodium salt, as it is an endogenous metabolite rather than a therapeutic agent. The compound is naturally present in all cells and is not known to be toxic. However, abnormal accumulation or depletion of this metabolite can be a sign of metabolic dysfunction. The compound is considered safe for handling in the laboratory under standard safety precautions.
|
| References |
|
| Additional Infomation |
CMP-Sialic acid sodium salt is a crucial nucleotide sugar involved in the biosynthesis of sialic acid-containing glycoconjugates. It serves as a substrate for Golgi sialyltransferases and as an allosteric inhibitor of UDP-GlcNAc 2-epimerase. This compound is widely used in the research of sialic acid-related diseases, such as cancer and viral infections. It plays a critical role in the proper function of cell surface glycoconjugates, which are involved in cell-cell recognition, signaling, and immune responses. As an endogenous metabolite, CMP-Sialic acid sodium salt is a valuable tool for studying sialylation and its role in health and disease.
|
| Molecular Formula |
C20H30N4NAO16P
|
|---|---|
| Molecular Weight |
636.432938098907
|
| Exact Mass |
636.129
|
| CAS # |
1007117-62-5
|
| Related CAS # |
CMP-Sialic acid;3063-71-6
|
| PubChem CID |
132285167
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
42
|
| Complexity |
1130
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
P(=O)([O-])(OCC1C(C(C(N2C(N=C(C=C2)N)=O)O1)O)O)OC1(C(=O)O)CC(C(C(C(C(CO)O)O)O1)NC(C)=O)O.[Na+]
|
| InChi Key |
VFRHSOGUONIUOR-HLZBELLTSA-M
|
| InChi Code |
InChI=1S/C20H31N4O16P.Na/c1-7(26)22-12-8(27)4-20(18(32)33,39-16(12)13(29)9(28)5-25)40-41(35,36)37-6-10-14(30)15(31)17(38-10)24-3-2-11(21)23-19(24)34;/h2-3,8-10,12-17,25,27-31H,4-6H2,1H3,(H,22,26)(H,32,33)(H,35,36)(H2,21,23,34);/q;+1/p-1/t8-,9+,10+,12+,13+,14+,15+,16+,17+,20+;/m0./s1
|
| Chemical Name |
sodium;[(2R,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl] [(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~125 mg/mL (~196.41 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5713 mL | 7.8563 mL | 15.7126 mL | |
| 5 mM | 0.3143 mL | 1.5713 mL | 3.1425 mL | |
| 10 mM | 0.1571 mL | 0.7856 mL | 1.5713 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
